14.04.2021 • News

ExxonMobil May Sell Elastomers Business

Exxon Mobil is exploring a sale of its Advanced Elastomer Systems (AES) division, potentially valuing it at around $800 million including debt, Reuters has reported, citing people familiar with the matter.

A deal could help the energy and petrochemicals group pare down some of its debt burden, which had risen to $45.5 billion at the end of 2020. Exxon has reportedly hired investment bank Morgan Stanley to solicit interest from potential buyers, including private equity investors.

After an historic loss of $22.4 billion last year, the Texas, USA-based group is struggling to convince investors that it can potentially rebound after years of overspending and a much criticized lack of investment in cleaner fuels.

In elastomers, Exxon is known for its Santoprene-brand thermoplastic vulcanizates (TPVs) used in automotive, industrial and consumer products. This business was launched in 1991 as a limited partnership between ExxonMobil Chemical and Solutia, then a spinout of Monsanto. Exxon took full ownership of it in 2002.

The global TPV market is poised to grow from $1.6 billion in 2019 to $2.6 billion in 2027, according to a report by ResearchAndMarkets.com. However, the industry has been adversely affected by the Covid-19 pandemic due to plant shutdowns and supply chain issues.

Author: Dede Williams, Freelance Journalist

Exxon Mobil is exploring a sale of its Advanced Elastomer Systems (AES)...
Exxon Mobil is exploring a sale of its Advanced Elastomer Systems (AES) division, potentially valuing it at around $800 million including debt, Reuters said. A sale could help pare down a $45.5 billion debt burden. The group reported an historic loss of $22.4 billion last year. (c) Tasos Mansour

Book

Innovation Management in Sustainable Chemistry

Innovation Management in Sustainable Chemistry

Comprehensive resource on sustainable chemistry, bridging the skill gap between academic science education and innovation and entrepreneurship

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read